The State-of-the-Art in the Management of Androgenetic Alopecia: A Review of New Therapies and Treatment Algorithms

The review highlights advancements in managing androgenetic alopecia (AGA) with both established and emerging therapies. Oral finasteride and topical minoxidil remain FDA-approved treatments, while low-dose oral minoxidil (LDOM) and dutasteride show promising results, particularly in male pattern hair loss (MPHL). For female pattern hair loss (FPHL), higher doses of finasteride and dutasteride are effective, though contraindicated in pregnancy. New therapies like oral contraceptives, spironolactone, bicalutamide, and mesotherapy with dutasteride show varying degrees of success. Platelet-rich plasma (PRP) therapy and other novel treatments like botulinum toxin and low-level light therapy (LLLT) also demonstrate potential. Investigational drugs such as pyrilutamide and SAMiRNA-AR68 are in advanced trial phases, while setipiprant and HMI-115 are in earlier stages. The review underscores the need for dermatologists to stay updated on these evolving treatment options.